Upregulated INHBA expression may promote cell proliferation and is associated with poor survival IN lung adenocarcinoma1 www.neoplasia.com

Neoplasia

Volumn 11, Issue 4, 2009, Pages 388-396

  Seder, Christopher W ^a   Hnrtojo, Wibisono ^a   Lin, Lin ^a   Silvers, Amy L ^a   Wang, Zhuwen ^a   Thomas, Dafydd G ^b   Giordano, Thomas J ^b   Chen, Guoan ^a   Chang, Andrew C ^a   Orringer, Mark B ^a   Beer, David G ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Department of Pathology   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACTIVIN A; FOLLISTATIN; INHIBIN A; MESSENGER RNA; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; TRICHOSTATIN A; HISTONE; HISTONE DEACETYLASE; INHIBIN; INHIBIN BETA A SUBUNIT; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION; ACETYLATION; ADENOCARCINOMA; BIOSYNTHESIS; CANCER STAGING; DNA METHYLATION; DNA MICROARRAY; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; ADENOCARCINOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBIN-BETA SUBUNITS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 65549129119     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81582     Document Type: Article

References (50)

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Homer MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2005/. [Based on November 2007 SEER data submission, posted to the SEER Web site]. Accessed April 1, 2008.
2. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. (2002). Gene-expression profiles pre- dict survival of patients with lung adenocarcinoma. Nat Med 6, 816-824.
3. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna- Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, et al. (2001). Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sd USA 98, 13784-13789. (Pubitemid 33115976)
4. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. (2001). Classification of human lung carci- nomas by mRNA expression profiling reveals disdnct adenocarcinoma subclasses. Proc NaU Acad Sd USA 98, 13790-13795. (Pubitemid 33115977)
5. Gaddy-Kurten D, Tsuchida K, and Vale W (1995). Activins and. the receptor serine kinase superfamily. Recent Prog Harm Res 50, 109-129.
6. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko R et al. (1988). Chemical, and. biological charac- terization of the inhibin family of protein hormones. Recent Prog Harm Res 44, 1.-34.
7. Lorenzen JR, Channing CP, and Schwartz NB (1978). Partial characterization of FSH suppressing activity (follicostatin) in porcine follicular fluid using the metestrous rat as an in vivo bioassay model. Biol Reprod 19, 635-640. (Pubitemid 9048083)
8. Boitani C, Stefanini M, Fragale A, and. Morena AR (1995). Activin stimulates Seroli cell proliferation in a defined period of rat testis development. Endocri- nology 136, 5438-5444.
9. Green JB, New HV, and Smith JC (1992). Responses of embryonic Xenopus cells to activin and FGF are separated by multiple dose thresholds and corre- spond to distinct axes of the mesoderm. CW/71, 731-739.
10. Smith JC, Price JMB, van Nimmen K, and Huylebroeck D (1990). Identifica- tion of a potent Xenopus mesoderm-inducing factor as a homologue of activin A. Nature 345, 729-731 (Pubitemid 20186552)
11. Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H, and Mori M (2003). Clinical significance of the expression of activin A in esophageal carci- noma. Int J Oncol 22, 75-80. [1.2] Yoshinaga K, Yamashita K, Mimori K, Tanaka F, Inoue H, and Mori M (2008). Activin A causes cancer cell aggressiveness in esophageal, squamous cell carci- noma cells. Ann Surg One 15, 96-103.
12. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, and Bradley A (1992). Alpha- inhibin is a tumor suppressor gene with gonadal specificity in. mice. Nature 360, 313-31.9. (Pubitemid 23000668)
13. Thomas TZ, Wang H, Nielasen P, O'Bryan MK, Evans LW, Groóme NP, Pedersen J, and Risbridger GP (1997). Expression and localization of activin sub- units and follistatins in tissues from men. with high, grade prostate cancer. J. Clin Endocrinol Metab 82, 3851-3858. (Pubitemid 27509382)
14. Kleeff J, Ishiwata T, Friess H, Biichlor MW, and Koro M (1998). Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 77, 860-868. [1.6] Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, and Felix JC (1998). Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 69, 23-31.
15. Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, and. Korc M (2001). Overexpression of activin A in stage IV colorectal cancer. Gut 49, 409-417. (Pubitemid 32802577)
16. Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Viganò P, Di Blasio AM, Genazzani AR, and Vale W (1998). Expression, and secretion of inhibin and activin in normal, and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J. Clin Endocrinol Metab 33, 1.194-1200. (Pubitemid 28496392)
17. Zhang Z, Zhao Y, Batres Y, Lin MF, and Ying SY (1997). Regulation of growth and prostatic marker expression by activin A in a androgen sensitive prostate cancer cell line LNCaR Biochem Biophys Res Comm 234, 362-365. (Pubitemid 27243908)
18. Dalkin AC, Gilrain JT, Bradshaw D, and Myers CE (1996). Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 137, 5230-5235. (Pubitemid 26423078)
19. McCarthy SA and Bicknell R (1993). Inhibition of vascular endothelial cell growth by activin A. J. Biol Chem 268, 23066-23071. (Pubitemid 23328013)
20. Liu QY, Niranjan B, Gomes P, Gomm JJ, Davies D, Coombes RC, and Buluwela L (1996). Inhibitory effects of activin on the growth and morphogenesis of pri- mary transformed mammary epithelial, cells. Cancer Res 56, 1.1.55-1163. (Pubitemid 26065416)
21. SternbergD, Honigwachs-Sha'ananiJ, Brosh N. MalikZ, BursteinY, andZipori D (1995). Restrictin-P/stromal activin A, kills its target cells via an apoptotic mecha- nism. Growth Factors 12, 277-287.
22. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, Asano S, and Kojima I (1993). Activin-A: an autocrine inhibitor of initiation of DNA synthe- sis in rat hepatocytes. J. Clin Invest 92, 1491-1496. (Pubitemid 23273929)
23. D'Amour KA, Agulnick AD, Eliazer S, Kelly OG, Kroon E, and Baetge EE (2005). Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat Biotechnol 23, 1534-1541.
24. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075.
25. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, and Minna JD (1985). Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45, 2913-2923. (Pubitemid 15232769)
26. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL, Misek DE, et al. (2003). Overexpression of oncopro- tein 1.8 correlates with poor differentiation in lung adenocarcinomas. MoI Cell Prot 2, 107-116.
27. Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, Misek DE, Greenson JK, Kardia SL, Beer DG, et al. (2001). Organ-specific molecular classification of primary lung, colon, and ovarian, adenocarcinomas using gene expression profiles. AmJPathol 159, 1.231-1.238. (Pubitemid 32947953)
28. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, and Beer DG (1997). Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 57, 5571-5578. (Pubitemid 28006766)
29. Lin J, Raoof DA, Wang Z, Lin MY, Thomas DG, Greenson JK, Giordano TJ, Orringer MB, Chang AC, Beer DG, et al. (2006). Expression and effect of inhibi- tion of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. Neoplasia 6, 1062-1071.
30. Gene Expression Omnibus Web site. Available at: http://www.ncbi.nlm.nih. gov /geo/. Accessed June 24, 2008.
31. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al. (2008). Gene expression signature of cigarette smoking and. its role in lung adenocarcinoma development and sur- vival. PLoS ONE 3 (2), el.651.
32. Son D, Kim S, Jo J, Kim H, Choi YH, Jung Y, Park M, Lim Y, Lee J, Lee E, et al. Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients- a Useful Prospective Clinical Practice. Available at: http://www.ncbi.nlm.nih.gov /geo/query/acccgi?accGSE8894. Accessed June 24, 2008.
33. de Caestecker MP, Piek E, and Roberts AB (2000). Role of transforming growth factor-beta signaling in cancer. J. Natl Cancer Inst 92, 1388-1402.
34. Massagué J, Blain SW, and Lo RS (2000). TGF-beta signaling in. growm control, cancer, and heritable disorders. Cell 103, 295-309.
35. Petraglia F, Garg S, Florio R Sadick M, Gallinelli A, Wong WL, Krummen L, Comitini G, Mather J, and Woodruff TK (1993). Activin A and activin B mea- sured in maternal, serum, cord blood, serum and amniotic fluid during human pregnancy. Endocr J1, 323-327.
36. Riley SC, Balfour C, Wathen NC, Chard T, Evans LW, Groóme NP, and Wallace EM (1998). Follistatin and activin A in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Hum Reprod 13, 2624-2628. (Pubitemid 28451252)
37. Luisi S, Battaglia C, Florio P, D'Ambrogio G, Taponeco F, Santuz M, Genazzani AR, and Petraglia F (1998). Acdvin A and inhibin B in extra-embryonic coelomic and amniotic fluids, and maternal serum in early pregnancy. Placenta 19, 435-438. (Pubitemid 28327704)
38. Fowler PA, Evans LW, Groóme NP, Templeton A, and Knight PG (1998). A longitudinal, study of maternal serum. inhibin-A, inhibin-B, activin-A, activin- AB, pro-C and follistatin during pregnancy. Hum Reprod 13, 3530-3536. (Pubitemid 29002653)
39. Wallace EM, D'Antona D, Shearing C, Evans LW, Thirunavukarasu P, Ashby JR Shade M, and Groóme NP (1999). Amniotic fluid levels of dimeric inhibins, pro-C inhibin, activin A and follistatin. in Down's syndrome. Clin Endocrinol 50, 669-673. (Pubitemid 29236345)
40. Muttukrishna S, Chamberlain R Evans LW, Asselin J, Groóme NR and Ledger WL (1999). Amniotic fluid concentrations of dimeric inhibins, activin A and follistatin in pregnancy. Eur J Endocrinol 140, 420-424. (Pubitemid 29254008)
41. Debieve F, Beerlandt S, Hubinont C, and Thomas K (2000). Gonadotropins, prolactin, inhibin A, inhibin B, and activin A in human fet al. serum from mid- pregnancy and term pregnancy. J. Clin Endocrinol Metab 85, 270-274. (Pubitemid 32268825)
42. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, and Bradley A (1995). Functional analysis of activins during mammalian develop- ment. Nature 374, 354-356.
43. Matzuk MM, Kumar TR, and Bradley A (1995). Different phenotypes for mice deficient in either activins or activin receptor type II. Nature 374, 356-360.
44. Ueno N, Ling N, Ying S-Y, Esch F, Shimasaki S, and Guillemin R (1987). Iso- lation and partial characterization of follistatin: a single-chain 35, 000 monomeric protein that inhibits the release of follicle stimulating hormone. Proc Natl Acad Sd USA 84, 8282-8286.
45. NakamuraT, Takio K, Eto Y, Shibai H, Titáni K, and Sugino H (1990). Activin binding protein from rat ovary is follistatin. Science 247, 836-838. (Pubitemid 20078560)
46. Hemmati-Brivanlou A, Kelly OG, and Melton DA (1994). Follistatin, an. antago- nist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell 77, 283-295. (Pubitemid 124000755)
47. WoodruffTKand Mather JP (1995). Inhibin, activin and female reproductive axis. Annu Rev Physiol 57, 219-244.
48. Klose RJ and Bird AP (2006). Genomic DNA methylation: the mark and its mediators. Trends Biochem Sei 31, 89-97. (Pubitemid 43221841)
49. Fuks F (2005). DNA methylation and. histone modifications: teaming up to silence genes. Curr Opin Genet Dev 15, 490-495. (Pubitemid 41262404)
50. microRNAorg Web site. Available at: www.microrna.org. Accessed May 29, 2008.